With stock trading at 19x FY19 PE and growth dependent on the challenging US business, Jefferies said it maintained hold rating with increased target price at Rs 510 (from Rs 480 earlier).

Cipla Q1 PAT may dip 46.52% YoY to Rs 199.6 cr: KR Choksey

Net Sales are expected to decrease by 4.43 percent Q-o-Q (down 4.78 percent Y-o-Y) to Rs 3332.5 crore, according to KR Choksey. Cipla to report net profit at 199.6 crore down 46.52% year-on-year.

Expect to see 18-20% growth for FY18: TCI Express

In an interview to CNBC-TV18, Chander Agarwal, MD & CEO, TCI Express spoke about the results and his outlook for the company.

Cipla Q4: Net profit seen at Rs 346.8 crore, revenues could rise to Rs 3,790 crore: Poll

Meanwhile, the earnings before interest, taxes, depreciation and amortisation could come in at Rs 675.4 crore, while its operating margin is seen at 17.8 percent.

Cipla Q4 PAT seen up 7.3% to Rs 326.3 cr: ICICI Securities

Net Sales are expected to increase by 5.6 percent Q-o-Q (up 17.9 percent Y-o-Y) to Rs 3852.5 crore, according to ICICI Securities. Cipla to report net profit at 326.3 crore up 7.3% quarter-on-quarter.

Cipla Q3 profit seen up 5%; US, India & EMs may lift revenue 20%

Analysts expect India business growth in range of 11-20 percent YoY while Africa and Rest of the World may report steady sales. API may see slower sales due to lower Nexium API supply.

Good Q3 but Dr Reddy's still far from sustainable growth: Expert

Surajit Pal, Research Analyst at Prabhudas Lilladher, said the pharma sector is undergoing a transition and all the large midcaps will underperform.

Cipla Q3 PAT seen up 8.2% to Rs 383.4 cr: ICICI Securities

Net Sales are expected to increase by 1.1 percent Q-o-Q (up 22 percent Y-o-Y) to Rs 3790.9 crore, according to ICICI Securities.

Cipla Q3 PAT may dip 2.6% to Rs 345 cr: KR Choksey

Net Sales are expected to decrease by 0.6 percent Q-o-Q (up 20.5 percent Y-o-Y) to Rs 3648.1 crore, according to KR Choksey.

Cipla Q2 profit seen down 13%, lower Nexium sales may hit margin

Pharmaceutical firm Cipla's second quarter profit is seen falling 13.4 percent year-on-year to Rs 373.34 crore on dismal operational performance. However, revenue may increase 9 percent to Rs 3,763.2 crore compared with year-ago period, according to average of estimates of analysts polled by CNBC-TV18.

Cipla Q2 PAT seen up 11.2% to Rs 406 cr: Centrum

Net Sales are expected to increase by 2.6 percent Q-o-Q (up 6.8 percent Y-o-Y) to Rs 3687 crore, according to Centrum.

Cipla Q1 profit seen down 41% to Rs 385 cr, revenue may be flat

Revenue is expected to be flat at Rs 3,865.8 crore in the quarter ended June 2016 against Rs 3,852.8 crore in year-ago period but may go up 18.3 percent QoQ.

Cipla Q1 PAT seen up by 315% at Rs 335.9 cr: Religare Research

Sales are expected to increase by 18.7 percent Q-o-Q (up 0.6 percent Y-o-Y) to Rs 3877.4 crore, according to Religare Research.

Cipla Q1 PAT seen up 522.4% to Rs 503.3 cr: Edelweiss

Net Sales are expected to increase by 21.7 percent Q-o-Q (up 3.2 percent Y-o-Y) to Rs 3976.4 crore, according to Edelweiss

Q1 earnings: Which sectors will do well, which won't?

In an interview with CNBC-TV18, Pankaj Pandey of ICICI Direct talked about the brokerage's expectations from the first quarter earnings season and outlined his view on various sectors.

Expect 10-15 launches in the US this year: Cipla

Initiatives are underway to normalise operations and the management is committed to making its EBITDA trajectory more sustainable in FY17, says Umang Vora, Global COO, Cipla.

Cipla Q4 profit seen up 39%, likely to meet FY16 growth guidance

Analysts polled by CNBC-TV18 say that Cipla is ikely to meet FY16 guidance of 15 percent growth and 150 basis points (bps margin expansion. The company is likely to guide for 20 percent sales growth for FY17 on account of support from Invagen.

Hold Cipla; on track to meet 20%+ EBITDA margins in'16: Religare

Praful Bohra of Religare is confident of the company clocking EBITDA margins of around 20.7 percent for FY16 and a similar number for FY17 too.

Cipla Q3 net seen up 26%; forex may hit ex-US export markets

As per analysts polled by CNBC-TV18, US business may be driven by continued supplies of Nexium API. Non-ARV (Anti-retroviral) tender business in South Africa & Germany is likely to steady. However, currency depreciation like South African Rand may impact ex-US export markets.

Lupin Q3: Prakash Diwan upbeat; Angle Broking neutral

Pharma major Lupin's third quarter earnings beat analysts' expectations on Friday. Revenue increased 13 percent to Rs 3,556 crore in quarter ended December 2015 compared to Rs 3,144.9 crore in year-ago period.

Cipla Q2 profit seen up 74% on export formulation biz boost

Nexium (used to treat certain stomach and esophagus problem) & Pulmicort (used to prevent asthma attacks) supply may boost company's export formulation business during the quarter. Hence, export formulation business may grow around 35-40 percent year-on-year.

Cipla Q1 profit seen up 47% on higher other income, revenue

In Q1FY15, other income declined 41 percent to Rs 40.39 crore, which impacted bottomline as well. The pharma company will announce its earnings on August 14.

Buy Dr Reddys at every dip; cautious on Cipla: IIFL

Given the numbers and the valuations the brokerage house would refrain from hiking the target price for Cipla from the current Rs 1070, Bhavesh Gandhi.

Sunshine stocks! Few positive surprises seen in weak Q1

Amid generally weak sales performance, sectors that are likely be stronger are IT (14 percent), pharma (12 percent), media & entertainment (12 percent) and retail (10 percent), says Emkay.

Q1 earnings to be tepid; analysts pick best & worst sectors

Weak commodity prices, delayed capex recovery and soft rural demand are the key factors that will weigh on June quarter corporate earnings, says CRISIL Research.